- Funding: National co-funding procedure for Bulgarian teams in approved COST Actions
- Contract: КП-06-КОСТ/25/12.12.2025 г.
- Principal Investigator: Assoc. Prof. Yordan Yordanov, PhD
- Scientific field: Medical sciences
- COST Action: CA24165 — Network for Cardiovascular Pharmacogenomics and Precision Medicine (CardioPharmaGENET)
- Host organization: Medical University of Sofia
- Project title: Pharmacogenomics applications of large language models and assessment of their impact on accessibility and readiness for integration in personalized cardiovascular pharmacotherapy
- Duration: 24 months
- Total budget: 50,000 BGN
Contact: yyordanov@pharmfac.mu-sofia.bg
Project summary
Pharmacogenomics (PGx) can improve therapy choice and dosing based on the patient’s genetic profile. This project tests whether chat-based interfaces powered by large language models (LLMs) can improve clinicians’ readiness to interpret and apply PGx information in cardiovascular pharmacotherapy.
A prototype intelligent agent will be developed and evaluated using anonymized example genomic data from public repositories. The project also includes regulatory, ethical, and socio-economic analyses to support safe and practical deployment.
Expected results
- Prototype agent integrating:
- PGx interpretation software (e.g., PharmCAT or alternatives)
- Open-access LLM models (e.g., biomedical models from Hugging Face)
- Documented internal and external testing results
- Evidence-based recommendations for implementation (including ethics, regulation, and pharmacoeconomics)
- Scientific outputs (publications / conference reports)
Work plan and stages (high level)
Stage 1 — Internal prototyping and controlled testing (months 1–12)
- Tool and guideline review; selection of PGx resources
- Infrastructure setup
- Agent development + internal testing + improvements
- Ethics and safety analysis based on pilot results
Stage 2 — External testing and impact analysis (months 12–24)
- Methodology for external evaluation (questionnaires / interviews)
- External testing with physicians/pharmacists
- Socio-economic and policy impact analysis
- Final contextual analysis and dissemination activities
Achieved results (to be updated)
- Stage 1: In progress
- Stage 2: Planned
(As you generate outputs, add them below with dates and links.)
Publications (Article 90 requirements)
Add publications here with links to journal pages and/or open-access copies.
- (planned) Publication 1 — TBD
- (planned) Publication 2 — TBD
Open data / resources
Add links to publicly accessible datasets and resources (where applicable).
- Example genomic data: public repositories (e.g., 1000 Genomes) — link(s) to be added
- Software / code repository — link(s) to be added
Intellectual property (if applicable)
- Patent / IP filing: Not applicable / To be assessed
Potential applications
- Support for clinicians to interpret PGx results faster and more consistently
- Improved accessibility to precision pharmacotherapy decision support
- Policy and implementation guidance for safe use of LLM-assisted PGx tools